about
Report from the OECI Oncology Days 2014Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trialEvaluating iatrogenic prescribing: development of an oncology-focused trigger tool.ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype.The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.Bystander effect of vinorelbine alters antitumor immune response.Physico-chemical stability of busulfan in injectable solutions in various administration packagesUse of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.Computerized pediatric oncology prescriptions review by pharmacist: A descriptive analysis and associated risk factors.Permeability of expander breast implants: In vitro and in vivo analyses.High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.High-dose thiotepa-related neurotoxicity and the role of tramadol in children.[Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study].Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC.[What are the expectations of coordination and accompaniment of French patients with cancer towards their community pharmacist?]Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapyAprepitant for paediatric chemotherapy-induced nausea and vomitingArsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon CancerTumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form[Study impacto: Descriptive analyzis of pharmacist's clinical practice in onco-hematology]
P50
Q35002560-D00219C5-F7FA-41CC-A771-1EDFC11A7181Q36279167-84B81685-5080-4396-B308-59D0CD025011Q38303963-F3186E4C-25CA-4D45-A8DC-917F1F3875ADQ38694788-F1EFB946-494C-4E2D-9598-40ACA6B925D7Q39139865-8335AB6C-C059-4F6D-ABB4-6353EE093354Q39624430-26C8D8A8-8970-4D8E-B29A-A7C473D3F7C2Q39861340-1269F650-9EB5-4A21-82CF-68E304EC070EQ40360434-59A34C97-E341-4038-A672-36C25BE4F8FCQ48101439-8CC8A70E-A4FE-40E8-AD87-CBE86E3EBB1AQ48499302-E34E6D30-5A44-4E02-A534-E0A69C32E892Q48887166-89568878-4D0B-4A09-B254-C991092D3011Q49991616-39B1222C-7263-48FB-BCFE-653893D90793Q50046503-D3351409-1A03-44FB-9D93-B7773E0B4FDDQ50519445-E7B32B6A-7F5F-4499-9748-F3C751DAFAC1Q51808589-2B86BA23-F245-402D-BF95-722DC04759B8Q52682622-DB8E639A-5206-4D91-9A93-CCF8E402D4F9Q57518018-B3ED4F42-F5D4-43F9-993F-3D667BB22353Q57518063-772DEC5B-A91C-4709-BC20-99F7F5EEF571Q62784039-0157F684-5A3E-4F96-BB78-0FC575ABC34DQ62784159-C38E4558-E7F5-43D9-9D85-FC3119635F95Q87230526-9C978B6A-920B-4D1E-8830-6151A52B99AA
P50
description
researcher ORCID ID = 0000-0001-8196-970X
@en
wetenschapper
@nl
name
François Lemare
@ast
François Lemare
@en
François Lemare
@es
François Lemare
@nl
type
label
François Lemare
@ast
François Lemare
@en
François Lemare
@es
François Lemare
@nl
prefLabel
François Lemare
@ast
François Lemare
@en
François Lemare
@es
François Lemare
@nl
P1153
24073433000
P21
P31
P496
0000-0001-8196-970X